Ignite Creation Date:
2024-05-06 @ 7:01 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05862285
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2023-05-01
Brief Title:
A Rollover Study for Participants Previously Enrolled in a Genentech andor F Hoffman-La Roche Sponsored Study
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Open-Label Multicenter Extension Study in Patients Previously Enrolled in a Genentech andor F Hoffmann-La Roche Ltd Sponsored Study
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
UmbrellaMAX
Brief Summary:
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product IMPs monotherapy or Roche IMPs combined with other agents or comparator agents for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-504263-16-00 | OTHER | EU Trial Number | None |
| 2022-003414-36 | EUDRACT_NUMBER | None | None |